SYNGENE
Syngene International Limited (SYNGENE) Stock Analysis
Syngene International Limited is a leading Indian contract research and manufacturing services (CRAMS) company. It provides integrated discovery, development, and manufacturing services to global pharmaceutical and biotechnology clients. Syngene is a subsidiary of Biocon and operates large R&D and production campuses in India. It is listed on the NSE and BSE.
Healthcare › Diagnostics & Research
₹444.30
+6.47% 1W | -33.10% 52W
Market Cap
17.9k CR
P/E Ratio
96.2
52W High
₹679
52W Low
₹344.4
Div. Yield
0.28%
Beta
0
50 DMA
₹386.1
200 DMA
₹416.4
Profit Margin
5.3%
Inst. Own.
39.1%
🔥 APPROACHING RESISTANCE
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 808.10 | 910.10 | 853.50 | 916.90 | 789.70 | 891.00 | 943.70 | 1,018.00 | 874.50 | 910.60 | 917.10 | 1,036.50 | 736.00 |
| Expenses | 596.20 | 656.00 | 622.00 | 600.00 | 619.90 | 646.20 | 660.10 | 674.40 | 668.10 | 711.10 | 707.90 | 733.10 | 645.20 |
| Operating Profit | 211.90 | 254.10 | 231.50 | 316.90 | 169.80 | 244.80 | 283.60 | 343.60 | 206.40 | 199.50 | 209.20 | 303.40 | 90.80 |
| OPM % | 26.22% | 27.92% | 27.12% | 34.56% | 21.50% | 27.47% | 30.05% | 33.75% | 23.60% | 21.91% | 22.81% | 29.27% | 12.34% |
| Other Income | 23.60 | 14.20 | 25.60 | 16.10 | 50.10 | 16.50 | 18.30 | 18.90 | 17.70 | 15.40 | -55.20 | 16.20 | 11.80 |
| Interest | 10.50 | 13.00 | 10.80 | 12.90 | 11.70 | 13.10 | 12.40 | 15.90 | 11.60 | 13.20 | 11.90 | 12.10 | 9.60 |
| Depreciation | 102.10 | 104.60 | 108.10 | 111.10 | 106.90 | 110.90 | 108.70 | 106.10 | 111.20 | 116.50 | 113.70 | 111.50 | 112.20 |
| Profit before tax | 122.90 | 150.70 | 138.20 | 209.00 | 101.30 | 137.30 | 180.80 | 240.50 | 101.30 | 85.20 | 28.40 | 196.00 | -19.20 |
| Tax % | 24.00% | 22.69% | 19.32% | 9.76% | 25.27% | 22.72% | 27.49% | 23.78% | 14.41% | 21.24% | 47.18% | 24.54% | -53.12% |
| Net Profit | 93.40 | 116.50 | 111.50 | 188.60 | 75.70 | 106.10 | 131.10 | 183.30 | 86.70 | 67.10 | 15.00 | 147.90 | -9.00 |
| EPS in Rs | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 | 1.67 | 0.37 | 3.67 | -0.22 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 | 3,600 |
| Expenses | 949 | 1,289 | 1,394 | 1,507 | 1,861 | 2,251 | 2,472 | 2,598 | 2,817 | 2,797 |
| Operating Profit | 474 | 537 | 618 | 678 | 743 | 942 | 1,017 | 1,045 | 921 | 803 |
| OPM % | 33% | 29% | 31% | 31% | 29% | 30% | 29% | 29% | 25% | 22% |
| Other Income | 53 | 75 | 153 | 94 | 75 | 63 | 77 | 101 | -9 | -12 |
| Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 49 | 47 |
| Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 453 | 454 |
| Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 411 | 290 |
| Tax % | 18% | 20% | 20% | 14% | 18% | 22% | 18% | 25% | 23% | |
| Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 317 | 221 |
| EPS in Rs | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 12.33 | 7.86 | 5.49 |
| Dividend Payout % | 7% | 3% | 0% | 0% | 10% | 11% | 10% | 10% | 16% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 5.0% | 11.0% | – |
| Profit CAGR | -8.0% | 0.0% | – |
Shareholding Pattern
Promoters52.68%
FIIs16.31%
DIIs24.62%
Public6.08%
Promoters52.68%
FIIs14.96%
DIIs25.83%
Public6.22%
Promoters52.68%
FIIs13.91%
DIIs26.44%
Public6.69%
Promoters52.59%
FIIs11.82%
DIIs28.01%
Public7.15%
Promoters52.59%
FIIs10.13%
DIIs29.31%
Public7.55%
Promoters54.88%
FIIs23.31%
DIIs10.71%
Public10.65%
Promoters54.79%
FIIs20.92%
DIIs15.80%
Public8.18%
Promoters52.74%
FIIs19.47%
DIIs21.50%
Public5.99%
Promoters52.68%
FIIs13.91%
DIIs26.44%
Public6.69%
Promoters52.59%
FIIs10.13%
DIIs29.31%
Public7.55%
SYNGENE
Holdings Analysis
Key strengths & risk signals
61
Overall
49
Fundamental
73
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 40.0% in the last year.
WEAK! Trading at 15.9% of 52W range - near yearly lows.
Strengths (3)
BREAKOUT! Stock has broken above resistance levels with momentum.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 1,139,517 vs down days: 509,835. Ratio: 2.24x
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
Fundamental & Technical Analysis
61Overall
49Fundamental
73Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 5.4% (MODERATE, 8/15). Profit CAGR: -12.0% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 6.1% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.32% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.12 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 10.23% public ownership - strong promoter/institutional control.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (386.0) is below 200-day average (429.5) - negative signal.
Price Position
6/10
MIXED POSITION! Current price (397.5) above 50-day but below 200-day.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
0/10
POOR YEAR! Stock declined 40.0% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 1,139,517 vs down days: 509,835. Ratio: 2.24x
RSI
3/5
BULLISH! RSI at 60.8 - positive momentum.
52W Range
1/5
WEAK! Trading at 15.9% of 52W range - near yearly lows.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 6.9% (1 week), 7.7% (1 month), -3.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
SYNGENE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-04 | Concall PDF | |
| Q2FY262026-01-29 | Concall PDF |
Peer Comparison
Healthcare · Diagnostics & Research · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹444.30 | 96.2 | 5.3% | 5.4% | -12.0% | -33.1% | 61 | BREAKOUT | – | -457.8% | – | +13.1% |
| VIJAYA | ₹1,410.10 | 71.4 | 22.4% | 21.0% | 26.9% | +36.7% | 77 | CONSOLIDATING DOWN | – | +12.1% | – | +10.6% |
| METROPOLIS | ₹564.20 | 52.4 | 12.6% | 12.8% | 10.0% | +17.3% | 66 | APPROACHING RESISTANCE | +42.9% | +32.8% | +15.8% | +10.4% |
| THYROCARE | ₹498.20 | 55.5 | 15.5% | 16.7% | 36.2% | -1.6% | 87 | BREAKDOWN | – | -69.5% | – | +12.8% |
| LALPATHLAB | ₹1,993.00 | 57.2 | 19.2% | 11.1% | 28.3% | +29.1% | 87 | CONSOLIDATING UP | – | +13.4% | – | +9.6% |
| VIMTALABS | ₹498.90 | 27.9 | 18.6% | 8.9% | 17.2% | -20.9% | 59 | BREAKDOWN | +3.5% | -1.9% | +10.0% | +2.7% |
| KRSNAA | ₹528.80 | 18.3 | 11.1% | 16.6% | 17.8% | -38.4% | 62 | APPROACHING SUPPORT | +2.9% | +48.2% | +31.6% | +15.1% |
| SURAKSHA | ₹341.70 | 49.7 | 11.0% | 17.7% | 70.3% | +14.9% | 83 | CONSOLIDATION | +38.3% | +106.3% | +20.7% | +7.6% |
Data from TradeAlone · Updated daily
SYNGENE News
Syngene International Limited (syngene) Q2 FY27: Revenue Growth Up 13%2026-10-27Syngene International Limited (SYNGENE) falls 8% intraday, breaks below support2026-07-30Syngene International Limited (syngene) Q1 FY27: Revenue at Rs. 736 Cr, Operating Ebitda at Rs. 91 Cr2026-07-29Syngene International Limited (syngene): Siddharth Mittal Appointed as Managing Director & CEO2026-07-01
